Search clinical trials for: Inhibitory control

Total 99724 results

RenJi Hospital
The First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaborators

Recruiting

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

China
European Organisation for Research and Treatment...
Merck Sharp & Dohme LLC; Swiss Group for Clinical Cancer Research

Not yet recruiting

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer (PROLoNg)

Oligometastatic Squamous Cell Carcinoma of the Head and Neck
AbbVie

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)

Rheumatoid Arthritis

United States, Japan, United Kingdom, Canada, Korea, Republic of, Puerto Rico, South Africa, Hungary, Bulgaria, Spain, Portugal, Croatia, France, Belgium, Chile, Germany, Greece, Romania, Brazil, Italy, Serbia, China, Colombia, Mexico
Centre Hospitalier Universitaire, Amiens
Central Hospital Saint Quentin

Recruiting

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment (Ibe2i-TIPCI)

Immunotherapy | Immune Checkpoint Inhibitors | Immune-related Adverse Event | Predictive Biomarkers

France
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
ANRS, Emerging Infectious Diseases
Gilead Sciences; Ministry of Health, Thailand; Assistance Publique - Hôpitaux... and other collaborators

Recruiting

Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France. (SimpPrEP)

HIV/AIDS

France, Thailand
Michael Hoelscher
Radboud University Medical Center; University College, London; University of...

Recruiting

PanACEA - STEP2C -01

Pulmonary Tuberculosis | Other Specified Pulmonary Tuberculosis

Gabon, South Africa, Tanzania, Malawi, Uganda, Mozambique
Hoffmann-La Roche

Recruiting

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

Korea, Republic of, United States, China, Spain, Germany, France, United Kingdom, Poland, Australia
Texas Tech University Health Sciences Center

Not yet recruiting

Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers (LOGIC)

Triple Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

Premenopausal Breast Cancer | Hormone-receptor-positive Breast Cancer | Breast Cancer Patients at Intermediate to High Risk | Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen

China
Mayo Clinic

Recruiting

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Gastric Adenocarcinoma | Clinical Stage IV Gastric Cancer AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Carcinoma | Metastatic Malignant Neoplasm in the Peritoneum

United States
Michael K. Gibson

Recruiting

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Recurrent Oropharyngeal Carcinoma | Metastatic Oropharyngeal Carcinoma

United States
Blokhin's Russian Cancer Research Center

Recruiting

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia (NEMO)

Breast Cancer | Neoadjuvant Endocrine Therapy

Russian Federation
Guangdong Provincial People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Non-Small Cell Lung Cancer | BRAF V600 Mutation | MET Amplification | MET Exon 14 Skipping Mutation | RET Driver Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

China
Chongqing University Cancer Hospital

Not yet recruiting

Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
Iterion Therapeutics

Recruiting

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

United States, Canada
Alliance Foundation Trials, LLC.
Genentech, Inc.

Recruiting

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

NSCLC

United States
Yonsei University

Recruiting

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

Endometrial Neoplasms | Endometrial Cancer

Korea, Republic of
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
King's College London
Guy's and St Thomas' NHS Foundation Trust

Recruiting

Mind and Skin - the Neurocutaneous Axis in Atopic Eczema

Atopic Dermatitis

United Kingdom
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo 170)

Non-Small Cell Lung Cancer

Korea, Republic of, United States, Australia, Brazil, China, United Kingdom, Israel, Belgium, Netherlands, Argentina, Spain, Taiwan, Canada, Italy, Poland, Turkey, Sweden, Switzerland
Olivia Newton-John Cancer Research Institute
Bristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaborators

Recruiting

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD BMS-986369, Rituximab +/- Nivolumab. (TOP-FLOR)

Follicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IV

Australia
TiumBio Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Solid Tumor

United States
DynamiCure Biotechnology

Recruiting

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States, Australia
Xuzhou Medical University

Recruiting

A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom

Lung Squamous Cell Carcinoma

China
Institute of Cancer Research, United Kingdom
Merck Sharp & Dohme LLC; Merck Serono GmbH, Germany

Recruiting

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC (POTENT)

Non Small Cell Lung Cancer | Advanced Cancer

United Kingdom
Fundació Institut Germans Trias i Pujol
Germans Trias i Pujol Hospital; University of Turin, Italy; Instituto de Salud... and other collaborators

Recruiting

Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment

HIV Infection Primary

Spain
Massachusetts General Hospital
William M. Wood Foundation

Recruiting

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Skin Cancer | Metastatic Melanoma

United States
National Cancer Institute (NCI)

Recruiting

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

United States
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Urothelial Carcinoma

China
Hoffmann-La Roche

Recruiting

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, United States, Canada, Turkey, Brazil, Spain, France, Germany, Australia, Italy, Belgium, Mexico
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Seagen Inc.

Not yet recruiting

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

United States
Yale University
Genentech, Inc.

Recruiting

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma

United States
Fudan University

Recruiting

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma (RAPID)

High-Risk Localized Soft Tissue Sarcoma

China
Hospital Universitario Dr. Jose E. Gonzalez

Recruiting

Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

Safety Issues | Efficacy, Self

Mexico
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (DETERMINE)

Melanoma | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Neoplasms by Site | Cancer | Colorectal Neoplasms | Endometrial Neoplasms | Malignant Neoplasm | Malignancy

United Kingdom
National Health Research Institutes, Taiwan
National Cheng-Kung University Hospital

Recruiting

Neoantigen Derived DCs as Cancer Treatment

Solid Tumor | Refractory Tumor

Taiwan
Centers for Disease Control and Prevention
Tuberculosis Trials Consortium

Recruiting

Short-course Regimens for the Treatment of Pulmonary Tuberculosis (CRUSH-TB)

Tuberculosis, Pulmonary | Tuberculosis Infection

Canada, United States, Haiti, South Africa, Uganda, Vietnam
Zhujiang Hospital

Recruiting

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Hepatocellular Carcinoma Resectable

China
University of California, San Francisco
Merck Sharp & Dohme LLC; Prostate Cancer Foundation

Recruiting

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Prostate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer

United States
University Hospital, Antwerp
Roche Pharma AG; Algemeen Ziekenhuis Maria Middelares; Kom Op Tegen Kanker; Vitaz

Recruiting

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma (Immuno-MESODEC)

Malignant Pleural Mesothelioma

Belgium
ImmunOs Therapeutics AG
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Solid Tumor, Adult

Australia
Vanderbilt-Ingram Cancer Center

Recruiting

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Refractory Melanoma

United States
Children's Oncology Group

Recruiting

A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage | Recurrent Acute Myeloid Leukemia... and other conditions

United States
1ST Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Advanced Solid Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Leap Therapeutics,...

Recruiting

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Endometrial Cancer

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

Head and Neck Tumors

China
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen...

Recruiting

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Metastatic Bladder Carcinoma | Urachal Adenocarcinoma | Locally Advanced Bladder Carcinoma | Malignant Renal Pelvis Neoplasm | Malignant Ureter Neoplasm | Malignant Urethral Neoplasm and other conditions

United States
Jiangxi Provincial Cancer Hospital

Recruiting

High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor (ST-CR01)

Metastatic Cancer

China
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma

United States

Search clinical trials for: Inhibitory control

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations